Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Tanya Burton, University Hospital of Wales, Cardiff, UK, discusses the recent approval of daratumumab with bortezomib and dexamethasone for multiple myeloma at first relapse in the UK. She highlights how this will impact both patient care and day units. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK,
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.